Dear Sir, Pursuant to provisions of Regulation 30 and other applicable provisions, if any, of the SEBI (LODR) Regulations, 2015, we hereby inform you that the Company plans to source injections portfolio of its products from a contract manufacturer, hence the Company shall discontinue production of injections at its manufacturing plant at Goa effective September 30, 2023. The Company is outsourcing manufacturing of the injections portfolio , with an intent to achieve cost efficiency and supply optimization. Said discontinuation of production at Company''s plant in Goa, shall not have an impact on continuity of sale of injections by the Company. Further details are mentioned in attached letter. Request you to kindly take note of the same and oblige.